<h4>Background and aims</h4>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major atherosclerotic cardiovascular events in individuals living with either diabetes or obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.